Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial - PubMed
9 hours ago
- #ileocaecal resection
- #Crohn's disease
- #infliximab
- The LIR!C trial compared laparoscopic ileocaecal resection to infliximab therapy for ileal Crohn's disease.
- 10-year follow-up showed ileocaecal resection had a higher therapy-free remission rate (35.8%) than infliximab (13.2%).
- Clinical remission rates were similar between groups (36.5% for resection vs. 28.4% for infliximab).
- Younger patients (20 years old) benefited more from resection, with a 30% higher remission rate compared to infliximab.
- The study supports ileocaecal resection as an early treatment option for ileal Crohn's disease.